drugset / Trial / NCT02547961
Chimeric Antigen Receptor-Modified T Cells for Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of HER2-CAR-T cell Infusion for advanced HER2 positive breast cancer.
Timeline
- Start
- 2015-09
- Primary completion
- 2016-08-15
- Completion
- 2016-08-15
Outcome
Outcome not reported
Stopped: “Project terminated due to revision of local regulations”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HER-2-targeting CAR T Cells | Cell therapy | — | Other |